Screening serum biomarkers for early primary hepatocellular carcinoma using a phage display technique

Zhang, Zhejia; Xu, Lei; Wang, Zhiming

doi:10.1002/jcla.20491

Cited by 13 publications

(12 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Homing peptides that specifically target HCC include TTPRDAY (Shimizu et al, 2006), FQHPSFI (HCBP1) (Zhang et al, 2007a), SFSIIHTPILPL (SP94) (Lo et al, 2008), RGWCRPLPKGEG (HC1) (Zhang et al, 2011), AGKGTPSLETTP (A54) (Du et al, 2010), KSLSRHDHIHHH (HCC79) (Jiang et al, 2006) and AWYPLPP (Jia et al, 2007). Several HCC-targeted delivery systems using these peptides have been developed (Du et al, 2010;Lo et al, 2008), but further studies are needed to confirm whether they can distinguish between HCC and hepatocytes or other liver cells.…”

Section: Homing Peptidesmentioning

confidence: 98%

Liver cell-targeted delivery of therapeutic molecules

Kang

Toita

Murata

2015

Critical Reviews in Biotechnology

View full text Add to dashboard Cite

The liver is the largest internal organ in mammals and is involved in metabolism, detoxification, synthesis of proteins and lipids, secretion of cytokines and growth factors and immune/inflammatory responses. Hepatitis, alcoholic or non-alcoholic liver disease, hepatocellular carcinoma, hepatic veno-occlusive disease, and liver fibrosis and cirrhosis are the most common liver diseases. Safe and efficient delivery of therapeutic molecules (drugs, genes or proteins) into the liver is very important to increase the clinical efficacy of these molecules and to reduce their side effects in other organs. Several liver cell-targeted delivery systems have been developed and tested in vivo or ex vivo/in vitro. In this review, we discuss the literature concerning liver cell-targeted delivery systems, with a particular emphasis on the results of in vivo studies.

show abstract

Section: Homing Peptidesmentioning

confidence: 98%

Liver cell-targeted delivery of therapeutic molecules

Kang

Toita

Murata

2015

Critical Reviews in Biotechnology

View full text Add to dashboard Cite

show abstract

“…In an unbiased approach, high-throughput screens without preselected antibodies or pathophysiology-based designs are used to identify novel biomarkers. 71 Numerous methods for unbiased biomarker discovery include phage-linked-enzyme-linked immunosorbent assay, 151 miRNA modulation, 5 and high-throughput proteomics techniques combined with bioinformatics. In hypothesis-driven discovery, biomarker candidates are selected based on their abundance in cells known to be affected by TBI.…”

Section: Biomarker Discovery: Current Prospects and Challengesmentioning

confidence: 99%

Sports-related brain injuries: connecting pathology to diagnosis

Pan¹,

Connolly²,

Dangelmajer³

et al. 2016

FOC

View full text Add to dashboard Cite

Neurosurg Focus 40 (4):E14, 2016M any sports-related brain injuries involve mild traumatic brain injuries (mTBIs), which result from physical blows to the head sustained over a period of time. Sports associated with an increased risk of head injury include American football, ice hockey, soccer, rugby, the martial arts, boxing, and bicycling. 21,90 These injuries are often unrecognized, undiagnosed, or underreported, which reflects the fact that this is a growing medical concern, often labeled a "silent epidemic." 8,66 Chronic exposure to mild brain injuries can result in long-term neurological consequences and represents a spectrum of disorders. The most remarkable outcome of mTBI is termed chronic traumatic encephalopathy (CTE), a clinical syndrome that is associated with neurodegeneration and behavioral, cognitive, and/or motor deficits. Although this disease has distinct pathological features, CTE is considered a diagnosis of exclusion because only postmortem biopsies can confirm the diagnosis. Therefore, new diagnostic methods need to be developed to: 1) inform patients of a definitive diagnosis, 2) better understand the epidemiology and risk factors of the disease, and 3) implement intervention programs to prevent any potential long-term complications. This review examines how understanding the pathology and molecular changes associated with repeated head trauma can lead to the discovery of novel imaging techniques and biomarkers. Mild Traumatic Brain Injury and CTEChronic traumatic encephalopathy has evolved from the so-called punch-drunk syndrome, which was used to describe a distinct neuropsychiatric condition that seemed to affect boxers, eventually becoming known as dementia pugilistica during the 1920s and 1930s. Symptoms such ABBrEvIATIoNs AD = Alzheimer's disease; APOE = apolipoprotein E; ASL = arterial spin labeling; BBB = blood-brain barrier; BOLD = blood oxygen level-dependent; CA = cornu ammonis; CTE = chronic traumatic encephalopathy; DTI = diffusion tensor imaging; FA = fractional anisotropy; fMRI = functional MRI; GFAP = glial fibrillary acidic protein; GRE = gradient recall echo; miRNA = microRNA; MRS = MR spectroscopy; mTBI = mild traumatic brain injury; NFL = National Football League; NFT = neurofibrillary tangle; NINDS = National Institute of Neurological Disorders and Stroke; NSE = neuron-specific enolase; p-tau = phosphorylated tau; SWI = susceptibility-weighted imaging; TDP-43 = TAR DNA-binding protein 43;18 F-FDDNP = 2-(1-{6- [(2-[fluorine-18] Brain injuries are becoming increasingly common in athletes and represent an important diagnostic challenge. Early detection and management of brain injuries in sports are of utmost importance in preventing chronic neurological and psychiatric decline. These types of injuries incurred during sports are referred to as mild traumatic brain injuries, which represent a heterogeneous spectrum of disease. The most dramatic manifestation of chronic mild traumatic brain injuries is termed chronic traumatic encephalopathy, which is associated with profo...

show abstract

“…Phage display has been successfully utilized to identify serum biomarkers in non-CNS disorders including ankylosing spondylitis (Wang et al, 2011), rheumatoid and osteoarthritis (Weng et al, 2012) (Araujo et al, 2015), heart disease (Park et al, 2010), hepatocellular carcinoma (Zhang et al, 2011), and lieshmaniasis (Coelho et al, 2015), and to identify a novel calpain inhibitor (Guttmann et al, 2005) but has not previously been applied to CNS disorders including TBI. Our results extend the utility of phage display to the discovery of serum TBI biomarkers.…”

Section: Discussionmentioning

confidence: 99%

Phage display for identification of serum biomarkers of traumatic brain injury

Ghoshal

Bondada

Saatman

et al. 2016

Journal of Neuroscience Methods

View full text Add to dashboard Cite

Background The extent and severity of traumatic brain injuries (TBIs) can be difficult to determine with current diagnostic methods. To address this, there has been increased interest in developing biomarkers to assist in the diagnosis, determination of injury severity, evaluation of recovery and therapeutic efficacy, and prediction of outcomes. Several promising serum TBI biomarkers have been identified using hypothesis-driven approaches, largely examining proteins that are abundant in neurons and non-neural cells in the CNS. New Method An unbiased approach, phage display, was used to identify serum TBI biomarkers. In this proof-of-concept study, mice received a TBI using the controlled cortical impact model of TBI (1 mm injury depth, 3.5 m/s velocity) and phage display was utilized to identify putative serum biomarkers at 6h postinjury. Results An engineered phage which preferentially bound to injured serum was sequenced to identify the 12-mer ‘recognizer’ peptide expressed on the coat protein. Following synthesis of the recognizer peptide, pull down, and mass spectrometry analysis, the target protein was identified as glial fibrillary acidic protein (GFAP). Comparison with Existing Methods and Conclusions GFAP has previously been identified as a promising TBI biomarker. The results provide proof of concept regarding the ability of phage display to identify TBI serum biomarkers. This methodology is currently being applied to serum biomarkers of mild TBI.

show abstract

Screening serum biomarkers for early primary hepatocellular carcinoma using a phage display technique

Cited by 13 publications

References 20 publications

Liver cell-targeted delivery of therapeutic molecules

Liver cell-targeted delivery of therapeutic molecules

Sports-related brain injuries: connecting pathology to diagnosis

Phage display for identification of serum biomarkers of traumatic brain injury

Contact Info

Product

Resources

About